FY26 OCRP PA Reference Table _Final.pdf
PDF 177 KB Posted
- Opportunity number
- HT942526OCRPIIRA
- Issued by
-
Department of the Army Medical Command
About this file
This is a reference table detailing award mechanisms and submission requirements for the Fiscal Year 2026 Congressionally Directed Medical Research Programs Ovarian Cancer Research Program (OCRP).
The document outlines six award mechanisms with varying eligibility criteria, funding levels, and deadlines. The Clinical Trial Award supports rapid implementation of clinical trials ranging from proof-of-concept to large-scale definitive trials for independent investigators at all academic levels, with maximum funding of $2.8 million over 4 years. The Investigator-Initiated Research Award targets investigators at or above the Assistant Professor level and provides up to $1.05 million (or $1.40 million for partnering PIs) over 4 years for non-clinical research. The Ovarian Cancer Academy–Early-Career Investigator Award supports new ECIs within five years of their last postdoctoral or clinical fellowship with $1.125 million over 4 years, while the Ovarian Cancer Clinical Trial Academy–Early-Career Investigator Award serves ECIs within 12 years of fellowship with $1.4 million over 4 years for clinical trial work. The Pilot Award targets postdoctoral or clinical fellows and provides $350,000 over 2 years for high-risk/high-reward innovative research. All awards require 4-year periods of performance except the Pilot Award (2 years). Pre-application deadlines range from July 13 to September 15, 2026, with full application submissions due October 1, 2026. Most mechanisms require preliminary data, and several mandate pre-application materials such as letters of intent or preproposals prior to full application submission.
OCRP Reference table
View the file
Other files
| File | Type | Posted |
|---|---|---|
| PKG00292634.pdf | ||
| HT942526OCRPIIRA_GG.pdf | ||
| HT942526OCRPIIRA_GG.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Fiscal Year 2026 Congressionally Directed Medical Research Programs Ovarian Cancer Research Program (OCRP)
Reference Table of Award Mechanisms and Submission Requirements
Award Mechanism Eligibility Key Mechanism Elements Funding Submission Deadline Clinical Trial Award Go to:
• Program Announcement
• General Application
Instructions
Grants.gov Funding Opportunity Number:
HT942526OCRPCTA
Independent investigators at all academic levels.
• Supports rapid implementation of clinical trials with the potential to significantly impact ovarian cancer.
• Proposed projects may range from small, proof-of concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1 or 1/2).
• Applications require preliminary data.
Larger, more definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population.
• Submission of a Letter of Intent is required prior to full application submission.
• The maximum period of performance is 4 years.
• The maximum allowable funding for the entire period of performance is $2.8 million (M) for total costs. *
Pre-Application (Letter of Intent):
September 15, 2026 5:00 p.m. Eastern time
Application:
October 1, 2026 11:59 p.m. Eastern time
Investigator-Initiated Research Award Go to:
• Program Announcement
• General Application
Instructions Grants.gov Funding Opportunity Number:
HT942526OCRPIIRA
Investigators at or above the level of Assistant Professor, or equivalent.
Partnering Principal Investigator (PI) Option:
Up to two investigators may collaborate on a single application, each of whom will serve as a PI and receive a separate award.
• Supports high-impact research that addresses a critical need and demonstrates the potential to make an important contribution to ovarian cancer or patient/survivor care.
o Applications cannot support clinical trials.
o Applications proposing research on cell lines or animals must provide justification for use.
o Research aimed at extending the lives of advanced state and recurrent patients encouraged.
o Applications require preliminary data.
Submission of a Preproposal is required; full application submission is by invitation only.
• The maximum period of performance is 4 years.
• Single PI: maximum allowable funding for the entire period of performance is $1.05M for total costs. *
• Partnering PI Option:
Maximum allowable funding for the entire period of performance is $1.40M for total costs. *
Pre-Application (Preproposal):
July 13, 2026 5:00 p.m. Eastern time
Application:
October 1, 2026 11:59 p.m. Eastern time
Ovarian Cancer Academy – Early-Career Investigator Award Go to:
• Program Announcement
• General Application
Instructions
Grants.gov Funding Opportunity Number:
HT942526OCRPOCAECI
Investigators must be within five years of their last postdoctoral research position or clinical fellowship or equivalent as of the full application submission deadline.
Requires a letter attesting to eligibility.
• Supports the addition of new early-career investigators to the unique, interactive, virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.
o Encourages applications from ECIs limited by lack of resources or other overwhelming obstacles, impacting their ability to commit to conducting ovarian cancer research.
o Requires a designated mentor who is an experienced ovarian cancer researcher with ovarian cancer funding.
o The ECI and designated mentor may originate from different institutions.
o Applications cannot support clinical trials. An ECI that wishes to propose a clinical trial may refer to the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award mechanism.
o Investigators who apply to both the Ovarian Cancer Academy – Early- Career Investigator Award and the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award mechanisms may not accept an award from both mechanisms.
• The maximum period of performance is 4 years.
• The maximum allowable funding for the entire period of performance is $1.125M for total costs. *
Pre-Application (Letter of Intent):
September 15, 2026 5:00 p.m. Eastern time
Application:
Ovarian Cancer Clinical Trial Academy – Early Career Investigator Award Go to:
• Program Announcement
• General Application
Instructions
Grants.gov Funding Opportunity Number:
HT942526OCRPOCCTAECI
Investigators must be within 12 years of their last postdoctoral research position or clinical fellowship or equivalent as of the full application submission deadline.
Requires a letter attesting to eligibility.
• Supports the addition of new ECIs to the unique, interactive, virtual Clinical Trial Academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.
o Encourages applications from ECIs limited by lack of resources or other overwhelming obstacles, impacting their ability to commit to conducting ovarian cancer research.
o Requires a designated mentor with clinical trial experience and an active clinical trial.
o A designated mentor may only mentor one ECI.
o The ECI and designated mentor may originate from different institutions.
o Applications require preliminary data.
o Clinical trials allowed.
o Investigators who apply to both the
Ovarian Cancer Academy – Early- Career Investigator Award and the Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award mechanisms may not accept an award from both mechanisms.
• Submission of a Letter of Intent is required prior to full application submission.
• The maximum period of performance is 4 years.
• The maximum allowable funding for the entire period of performance is $1.4M for total costs. *
Pre-Application (Letter of Intent):
September 15, 2026 5:00 p.m. Eastern time
Application:
*Total costs include direct and indirect costs.
Pilot Award Go to:
• Program Announcement
• General Application
Instructions
Grants.gov Funding Opportunity Number:
HT942526OCRPPA
Investigators at the level of postdoctoral fellow or clinical fellow, or equivalent.
• Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.
o Innovation is an important review criterion.
o The goal is to develop preliminary data; thus, preliminary data are not required but are allowed.
o Applications cannot support clinical trials.
o Encourages research aimed at extending the lives of advanced-state and recurrent patients.
• Reviewers will be blinded to the identity of the PI, collaborators and their organization(s).
• The OCRP requires submission of a Preproposal and will blind reviewers to the names of investigators and organizations during review; full application submission is by invitation only.
• Clinical trials are not allowed.
• The maximum period of performance is 2 years.
• The maximum allowable funding for the entire period of performance is $350,000 for total costs. *
Pre-Application (Preproposal):
July 13, 2026 5:00 p.m. Eastern time
Application:
File details come from the government source that posted it. Updated .